Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cytodyn Inc
(OP:
CYDY
)
0.2369
+0.0009 (+0.38%)
Streaming Delayed Price
Updated: 3:59 PM EST, Feb 19, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cytodyn Inc
< Previous
1
2
3
4
Next >
CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC Laboratories
February 06, 2025
From
CytoDyn Inc.
Via
GlobeNewswire
December 2024 Letter to Shareholders
December 17, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in Oncology
November 25, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial
November 04, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC Laboratories
October 30, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development
October 08, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces Abstract that Highlights Leronlimab’s Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques
October 07, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial
October 04, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces Preliminary Findings in Study with SMC Laboratories
September 24, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
September 2024 Letter to Shareholders
September 09, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Engages Leading CRO For Phase II Inflammation Trial
August 23, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer
August 12, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces Settlement with Amarex Clinical Research LLC
July 09, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024
June 27, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn to Host Webcast to Provide Company Update
May 28, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
May 2024 Letter to Shareholders
May 16, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces FDA Has Lifted Clinical Hold
February 29, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma
February 01, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO
January 29, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces Webcast to Provide Company Update
December 07, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO
November 21, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
November 2023 Letter to Shareholders
November 03, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces Company Updates and Investment Community Update Webcast
July 11, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces President Takes Medical Leave of Absence
May 24, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn to Hold Webcast to Provide a Company Update
April 05, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
Trading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group's Most Active List In December
January 17, 2023
On December 14th, the Federal Reserve hiked its key interest rate by 50 basis points. This was the first deceleration in rate hike increases in 2022; between March and November 2022, the interest rate...
Via
Benzinga
CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO
December 23, 2022
From
CytoDyn Inc.
Via
GlobeNewswire
OTC Market Group's Most Active List In November: A Dive Into The Names Experiencing Volume Changes
December 13, 2022
The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) increased by 5.56% in November, recording two subsequent monthly increases for the first time in 2022.
Via
Benzinga
CytoDyn to Host R&D Update on Wednesday, December 7, 2022
November 22, 2022
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues
October 28, 2022
From
CytoDyn Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
